Leidos’ biomedical research business has tapped Tempus to collate and summarize follow-up clinical data for a National Cancer Institute project that aims to provide data that will contribute to improved cancer diagnosis and treatment.
Tempus said Tuesday it has collaborated with Leidos to secure and consolidate updated medical records from 230 contributors as part of the Cancer Genome Atlas program.
Utilizing its Tempus O system, the company will filter and summarize the collected clinical data prior to their alignment with molecular information. NCI plans to release the completed dataset publicly for researchers’ usage.
“We are pleased to support the NCI and the many medical centers whose investigators have contributed to TCGA, and we are eager to integrate these important datasets in pursuit of research and improved patient care," said Kevin White, president at Tempus.
Jointly established by NCI and the National Human Genome Research Institute in 2006, the TCGA initiative has categorized more than 20K cancer and matched normal samples and validated 33 different cancer types.